During the extended session on Tuesday, Myriad Genetics, Inc. (NASDAQ: MYGN) had a significant 38.24% increase in its stock price, reaching $5.35. Following the announcement of its impressive second-quarter results, which demonstrated great operational performance, positive market trends, and strategic development objectives, there was a sudden spike in after-hours trading.
Robust Q2 Performance Driven by Cancer Testing Strength
Myriad Genetics reported $213.1 million in sales for the second quarter of 2025, a 1% increase from the previous year. Stronger average revenue per test, greater laboratory efficiency, and product mix optimization all contributed to the gross margin’s improvement to 71.2%, up more than 160 basis points from the previous year.
Growth was sustained by the company’s oncology hereditary cancer diagnostics as well as rising adoption among unaffected people.
Prioritizing the Cancer Care Continuum Strategically
Three main pillars have been the focus of Myriad Genetics’ thorough examination of its long-term growth plan. First and foremost, the firm intends to increase its position in the Cancer Care Continuum (CCC) by expanding its testing offering to encompass Molecular Residual Disease (MRD) diagnostics, immuno-oncology therapy monitoring, and therapy selection.
The proprietary MRD test is expected to enter early access launch in the first half of 2026. Investments in research, development, commercial capabilities, and customer digital experience are being prioritized to better capture CCC opportunities.
Financing and Operational Discipline to Support Growth
To enhance financial flexibility, Myriad Genetics entered into a new $200 million credit facility on July 31, 2025. Additionally, it secured non-dilutive financing from OrbiMed to bolster long-term initiatives.
The company also aims to grow Prenatal Health revenue through recently launched tests, including the Prequel NIPS test, and plans the commercial debut of the FirstGene Multiple Prenatal Screen in 2026. In Mental Health, emphasis will be placed on high-value GeneSight accounts and leveraging favorable biomarker legislation.
Myriad Genetics projects high single-digit to low double-digit revenue growth over the next five years, complemented by margin expansion through cost discipline, operational efficiency, and stable pricing strategies.
